KADIMASTEM LTD Inactive Instrument
Kadimastem Ltd Stock TEL AVIV STOCK EXCHANGE
Equities
IL0011284614
Biotechnology & Medical Research
| Sales 2022 | - | Sales 2023 | - | Capitalization | 24.87M 9.45B |
|---|---|---|---|---|---|
| Net income 2022 | -22M -8.36B | Net income 2023 | -12M -4.56B | EV / Sales 2022 | - |
| Net Debt 2022 | 739K 281M | Net Debt 2023 | 2.17M 825M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-1.76
x | P/E ratio 2023 |
-2.12
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 39.92% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Asaf Shiloni
CEO | Chief Executive Officer | 54 | 21-01-31 |
Michel Revel
FOU | Founder | 85 | 08-10-05 |
Uri Ben-Or
DFI | Director of Finance/CFO | 52 | 22-06-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 72 | 20-12-16 | |
Tamar Galili
BRD | Director/Board Member | 51 | 22-01-02 |
Ronen Twito
CHM | Chairman | 49 | 20-12-22 |
Kadimastem Ltd is an Israel-based regenerative medicine company focused on the industrial development and commercialization of stem cell-based therapeutics, primarily for diabetes and neurodegenerative disorders. The Companyâs technology enables the differentiation of stem cells into insulin secreting beta cells, as well as a range of neural cells (including Oligodendrocytes, Astrocytes). The Company produces islet-like clusters that show glucose-stimulated insulin secretion. In addition, the Company is partnering with pharmaceutical companies interested to screen potential drug compounds (hit-lead, lead optimization) on its stem-cell derived cells, primarily oligodendrocytes and astrocytes.
| 1st Jan change | Capi. | |
|---|---|---|
| -3.28% | 104B | |
| -0.06% | 97.42B | |
| +1.31% | 22.2B | |
| -18.25% | 21.23B | |
| -10.74% | 18.33B | |
| -42.83% | 16.35B | |
| -17.17% | 15.06B | |
| +3.60% | 13.98B | |
| +27.51% | 11.66B |
